Leadership Team
Putting decades of industry experience to work for our customers.
Chris Giordano
President
Chris Giordano serves as president of IQVIA Biotech Clinical Solutions and held the same position at Novella Clinical,
a Quintiles company prior to the launch of IQVIA Biotech. Mr. Giordano brings a deep operational knowledge of clinical
trial planning and execution from 20 years in the CRO industry, supporting sponsors in Europe, Japan and North America.
Prior to leading Novella Clinical, Mr. Giordano was global head of the Cardiovascular, Renal and Metabolic Therapeutic
Area at IQVIA, where he also led portfolio-wide, end-to-end development alliances with several biopharma sponsors. Mr.
Giordano was responsible for global delivery of trials across all phases of development and therapeutic areas in these
partnerships. His responsibilities have increased over time from biotech sales, broad business development, trial
delivery and joint scientific collaborations with academic research organizations.
Chris earned a bachelor’s degree from the University of San Diego, spent a year as a visiting student at St.
Catherine’s College, Oxford, and earned an MA from the University of North Carolina at Chapel Hill.
Chris Smyth, PhD, MBA
Chief Operating Officer
Dr. Chris Smyth is chief operating officer for IQVIA Biotech and served in the same position at Novella Clinical, a
Quintiles company prior to the launch of IQVIA Biotech. He is responsible for global oversight of project management,
clinical, regulatory and data services as well as developing and implementing strategic direction for the business.
He has led clinical research organizations and biopharmaceutical companies in both Europe and the US. Dr. Smyth has
more than 20 years oncology research and development experience in the pharmaceutical industry and most recently served
as head of the Oncology division at Novella Clinical.
Chris holds a PhD in Reproductive Biology from the University of Edinburgh and an MBA. from Henley Management College,
United Kingdom.
James Kyle Bryan, MD
Chief Medical Officer
Dr. James Kyle Bryan is chief medical officer for IQVIA Biotech and served in the same position at Novella Clinical, a
Quintiles company prior to the launch of IQVIA Biotech. He has more than 20 years of experience in drug discovery and
development in the pharmaceutical and biotechnology industries in both the sponsor and CRO arenas. Dr. Bryan provides
medical and safety leadership to all clinical projects as well as bringing valuable insights into clinical development
and regulatory strategy to our clients.
Dr. Bryan is board-certified in medical oncology and hematology, and remains engaged in clinical work, holding an
appointment on the clinical faculty of medicine for hematology and oncology at the University of Washington Medical
Center. Prior to joining Novella Clinical, Dr. Bryan served as chief medical officer for VentiRx Pharmaceuticals and
vice president of medical affairs for Seattle Genetics.
Kyle holds a bachelor’s degree in Biochemistry and an MD from Louisiana State University. He completed his fellowship
in hematology and oncology at the University of Washington.
JCharles Lambert
Chief Financial Officer
Charles Lambert is chief financial officer for IQVIA Biotech and served in the same position at Novella Clinical, a
Quintiles company prior to the launch of IQVIA Biotech. As an integral part of the management team, he develops
strategies to maintain fiscal health and strong growth trajectory.
Prior to joining Novella Clinical, Mr. Lambert spent 12 years in the healthcare IT sector, serving as CFO for Misys
Healthcare Systems and Capario. Throughout his career, he has held numerous executive-level positions within the
healthcare, technology and industrial sectors across the US, Europe and Asia.
Charles holds a master’s degree in Economics from Cambridge University
in the United Kingdom and is a qualified Chartered Accountant.
Anusha Foy, BSc, LLB
Global Head of Regulatory Affairs
Anusha Foy, BSc, LLB, is responsible for leading IQVIA Biotech’s global regulatory affairs department and served in the
same capacity at Novella Clinical, a Quintiles company prior to the launch of IQVIA Biotech.
She oversees regulatory clinical research projects, safety reporting for customers, and provides the project team with
guidance, training and strategic planning.
Ms. Foy has more than 15 years of regulatory affairs experience globally across many therapeutic areas including
oncology, CNS and respiratory research. Prior to joining Novella Clinical, Ms. Foy held senior regulatory affairs roles
at a variety of organizations including the Medicines and Healthcare products Regulatory Agency (MHRA) and two global
CROs.
She holds a BSc in Medicinal Chemistry from University College London;
a Bachelor of Law from Birkbeck College London and qualified as
a non-practicing Barrister in England and Wales.
Ray Reilly
Vice President, Clinical Monitoring
Ray Reilly is vice president, clinical monitoring for IQVIA Biotech and served in the same position at Novella
Clinical, a Quintiles company prior to the launch of IQVIA Biotech. He is responsible for the global clinical
monitoring division. His more than 20 years industry experience includes work with clinical research organizations and
biopharmaceutical companies.
Mr. Reilly possesses extensive knowledge of clinical trial management, research processes, and regulations and
guidelines. His previous positions span a range of functions, including clinical monitoring, regulatory/QA, clinical
training and project management.
Ray holds a bachelor’s degree in Biology from the University of North Carolina at Chapel Hill.